Nouvelle déclaration d'incident
No de la demande: 2021-0392
Numéro de référence du titulaire d'homologation: 2020-US-037536, US-037544, US-037545 Linked cases
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: WEST VIRGINIA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-140
Nom du produit: Hartz UltraGuard Plus Flea and Tick Spray for Cats
Liquide
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Cat / Chat
Domestic Mediumhair
1
Homme
1
10
lbs
Cutanée
Unknown / Inconnu
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 18-Oct-2020, a 1 year old, approximately 10 pound, intact, male, Domestic Mediumhair cat, in unknown condition, with no known concomitant medical conditions, was administered 1 application of Hartz UltraGuard Plus Flea and Tick Spray for Cats (Methoprene / Tetrachlorvinphos) via the topical route by the animal owner. This was a first time use of the product. On 19-Oct-2020, the cat was unable to rise and then died an unspecified amount of time later. The cat had not been evaluated by a veterinarian, no treatment had been performed and it is unknown if a necropsy was pursued. No further information was received.
Mort
Assessment: The active ingredients in this product are present in low concentration and has a wide margin of safety in cats. If a small amount was ingested, only minor GI upset would be expected. Other causes should be considered in this case including unknown trauma, underlying disease, and unknown exposure to a toxin. Without veterinary evaluation and diagnostics, including necropsy, this case cannot be evaluated further. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.
Propriétaire de l'animal
Cat / Chat
Domestic Mediumhair
1
Homme
1
10
lbs
Cutanée
>8 hrs <= 24 hrs / >8 h <= 24 h
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 18-Oct-2020, a 1 year old, approximately 10 pound, intact, male, Domestic Mediumhair cat, in unknown condition, with no known concomitant medical conditions, was administered 1 application of Hartz UltraGuard Plus Flea and Tick Spray for Cats (Methoprene / Tetrachlorvinphos) via the topical route by the animal owner. This was a first time use of the product. On 19-Oct-2020, the cat developed vocalization. Approximately four hours later, the cat died. The cat was not evaluated by a veterinarian, no treatment had been performed and it is unknown if a necropsy was pursued. No further information was received.
Mort
Assessment: The active ingredients in this product are present in low concentration and has a wide margin of safety in cats. If a small amount was ingested, only minor GI upset would be expected. Other causes should be considered in this case including unknown trauma, underlying disease, and unknown exposure to a toxin. Without veterinary evaluation and diagnostics, including necropsy, this case cannot be evaluated further. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.
Propriétaire de l'animal
Cat / Chat
Siamese
1
Homme
0.15
3
lbs
Cutanée
>8 hrs <= 24 hrs / >8 h <= 24 h
>24 hrs <=3 days / >24 h <=3 jours
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 18-Oct-2020, an 8-week old, approximately 3 pound, intact, male, Siamese cat, in unknown condition, with no known concomitant medical conditions, was administered 1 application of Hartz UltraGuard Plus Flea and Tick Spray for Cats (Methoprene / Tetrachlorvinphos) via the topical route by the animal owner. This was a first time use of the product. This was extra label use as the product is not intended for use on cats under 12 weeks of age. On 19-Oct-2020, the cat developed vocalization. Approximately four hours later, the cat died. The cat was not evaluated by a veterinarian, no treatment had been performed and it is unknown if a necropsy was pursued. No further information was received.
Mort
Assessment: The active ingredients in this product are present in low concentration and has a wide margin of safety in cats. Even in the event of misuse, severe signs and death are not expected. If a small amount was ingested, only minor GI upset would be expected. Other causes should be considered in this case including unknown trauma, congenital conditions, and unknown exposure to a toxin. Without veterinary evaluation and diagnostics, including necropsy, this case cannot be evaluated further. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.